Literature DB >> 1980821

Trends in survival of Danish AIDS patients from 1981 to 1989.

C Pedersen1, J Gerstoft, P Tauris, J D Lundgren, P C Gøtzsche, M Buhl, Y Salim, K Schmidt, J O Nielsen.   

Abstract

Length of survival was analysed in relation to year of diagnosis, AIDS-indicative disease, age, risk behaviour, zidovudine therapy, and CD4 cell count and serum immunoglobulin (Ig) levels at the time of diagnosis in a group of 231 consecutive adult Danish AIDS patients reported before 1 January 1988. The cumulative survival rate was 53% (95% confidence interval 47-59%) at 1 year, 29% (22-36%) at 2 years and 18% (10-26%) at 3 years. Length of survival increased significantly (P less than 0.001) over time for patients who were initially diagnosed with Pneumocystis carinii pneumonia (PCP), 17% (3-31%) at 2 years prior to 1986, 32% (16-49%) in 1986 and 52% (34-69%) in 1987, whereas survival remained stable for patients with other AIDS-indicative diseases. Survival was similar for patients who were diagnosed with Kaposi's sarcoma alone and PCP alone. Independent predictors of a shortened survival were a CD4 cell count less than 200 x 10(6)/l, a serum IgA level greater than 4 g/l, and an initial diagnosis with opportunistic infections other than PCP. In addition, the multivariate analysis suggested an improved survival in recent years for patients diagnosed with PCP, independent of other factors examined. We conclude that length of survival in AIDS patients is highly variable. Determinants of progression include CD4 cell count, serum IgA level, and presenting disease. Survival has increased markedly for patients with PCP and median survival now exceeds 24 months.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980821     DOI: 10.1097/00002030-199011000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Survival after AIDS diagnosis in Tuscany (Italy), 1985-1992.

Authors:  A Barchielli; S Acciai; V Lazzeri; E Buiatti
Journal:  Eur J Epidemiol       Date:  1997-02       Impact factor: 8.082

2.  Survival differences in Austrian patients with the acquired immunodeficiency syndrome.

Authors:  R Zangerle; G Reibnegger; J P Klein
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

3.  Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group.

Authors:  J D Lundgren; C Pedersen; N Clumeck; J M Gatell; A M Johnson; B Ledergerber; S Vella; A Phillips; J O Nielsen
Journal:  BMJ       Date:  1994-04-23

4.  What is the role of CD4 count in a large public health antiretroviral programme?

Authors:  Michelle Moorhouse; Francesca Conradie; Francois Venter
Journal:  South Afr J HIV Med       Date:  2016-02-12       Impact factor: 2.744

5.  Assessment of the AQUIOS flow cytometer - An automated sample preparation system for CD4 lymphocyte PanLeucogating enumeration.

Authors:  Daniel Rhodes; Guislaine Carcelain; Mike Keeney; Christophe Parizot; Dominika Benjamins; Laurine Genesta; Jin Zhang; Justin Rohrbach; Denise Lawrie; Deborah K Glencross
Journal:  Afr J Lab Med       Date:  2019-12-05

6.  Low Risk of CD4 Decline After Immune Recovery in Human Immunodeficiency Virus-Infected Children With Viral Suppression.

Authors:  Pope Kosalaraksa; David C Boettiger; Torsak Bunupuradah; Rawiwan Hansudewechakul; Sarun Saramony; Viet C Do; Tavitiya Sudjaritruk; Nik K N Yusoff; Kamarul A M Razali; Lam V Nguyen; Revathy Nallusamy; Siew M Fong; Nia Kurniati; Khanh H Truong; Annette H Sohn; Kulkanya Chokephaibulkit
Journal:  J Pediatric Infect Dis Soc       Date:  2017-06-01       Impact factor: 3.164

7.  Early ART in Acute HIV-1 Infection: Impact on the B-Cell Compartment.

Authors:  Robert Badura; Russell B Foxall; Dario Ligeiro; Miguel Rocha; Ana Godinho-Santos; Amelia C Trombetta; Ana E Sousa
Journal:  Front Cell Infect Microbiol       Date:  2020-07-16       Impact factor: 5.293

8.  Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV.

Authors:  Bogusz Jan Aksak-Wąs; Miłosz Parczewski; Anna Urbańska; Małgorzata Hackiewicz; Justyna D Kowalska
Journal:  PLoS One       Date:  2021-08-09       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.